Bluejay Diagnostics completes prefunded warrant exercises

Bluejay Diagnostics Inc. (NASDAQ: BJDX) announced that all prefunded warrants from its October 2025 private placement have been exercised as of February 19. The medical diagnostics company now has approximately 972,000 shares of common stock outstanding.

The company retains outstanding cash exercisable warrants for approximately 1.5 million shares, all with exercise prices of $7.00 or higher per share.

Bluejay noted that recent Schedule 13G filings by investors may not reflect the 1-for-4 reverse stock split completed on January 29. The company stated that current beneficial ownership amounts may be significantly lower than figures shown in these reports, which display holdings on a pre-split basis.

The Acton, Massachusetts-based company develops the Symphony System, a rapid testing platform for sepsis diagnosis. The system does not have regulatory clearance from the U.S. Food and Drug Administration. The company's IL-6 Test candidate is designed to provide results within approximately 20 minutes.

You May Also Be Interested In